Chemicon International and Stem Cell Sciences Announce Launch of ESGRO Complete(TM) Product Line.

ATLANTA -- New Grade of Serum and Feeder-Free Media for Mouse Embryonic Stem Cell Expansion

Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, and Stem Cell Sciences plc (LSE:STEM, SCS) are launching the ESGRO Complete(TM) product line for murine embryonic stem (ES) cell culture, following the establishment of an exclusive agreement on November 3, 2005.

Chemicon will exclusively market the licensed ESGRO Complete(TM) Clonal Grade Medium for serum-free, feeder-free expansion of mouse ES cells. The product, developed by SCS's SC Proven division, is the first complete, defined medium that enables the large-scale, consistent production of mouse ES cells for the use in world-wide research and drug discovery markets. To complement the offering, Chemicon will be releasing other media and reagents needed for routine mouse ES cell culture that have been specifically engineered and validated for use in this serum-free system. The ESGRO Complete(TM) product line will broaden Chemicon's offering within the stem cell culture market and will complement the current portfolio of innovative reagents and technologies that are already being supplied to its customer base.

"The ESGRO Complete(TM) product line is a great leap forward over the existing methodologies used by stem cell researchers today," said Jeffrey D. Linton, President of Chemicon and Upstate, Serologicals' Research Segment companies. "This is a culmination of our earlier agreement with Stem Cell Sciences to commercialize this technology through our Research segment, and is yet another example of how Chemicon is establishing itself as a leading company in the stem cell research arena."

"We are very excited about the launch of our first cell culture media product. This will generate revenue streams in the near term and marks a major milestone in our development," said Peter Mountford, CEO of Stem Cell Sciences plc. "The launch validates our technology and will contribute to the wider adoption of stem cells within the global drug discovery market. We look forward to our continued collaboration with Chemicon and the opportunity to expand the stem cell culture product offering in due course."

Chemicon International, Inc. offers a broad range of research products, including specialty reagents, kits, antibodies, and custom products and services, to customers working in the areas of neuroscience, stem cell biology, cancer, and infectious disease research. It is also a leading supplier of monoclonal antibodies, conjugates, antibody blends and molecular-based detection kits for use in diagnostic laboratories. Chemicon focuses on basic and biomedical research, drug discovery, and diagnostics, allowing it to serve thousands of customers worldwide in the academic, clinical, biotechnology, and pharmaceutical sectors. Acquired in 2003, Chemicon is a Serologicals company, based in Temecula, CA.

For more information, please visit our website: www.chemicon.com.

Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA, is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of life-enhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world's leading provider of monoclonal antibodies for the blood typing industry. Serologicals employs a total of more than 1,000 people worldwide in three Serologicals' companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA, and Celliance Corporation, headquartered in Atlanta, GA.

For more information, please visit our website: www.serologicals.com.

Stem Cell Sciences plc (SCS) is a global biotechnology company focused on the development of stem cell technologies. The Company has established a leading intellectual property (IP) and technology portfolio that enables the commercial application of stem cells in pharmaceutical and biotechnology drug discovery, providing the Company with an early-stage revenue stream. In the longer term, the Company is developing regenerative, cell-based therapies.

Stem Cell Sciences has four business units focused on key sustainable business strategies. SC Proven provides serum free, cell culture media and reagents that enable the growth of stem cells. The first commercially available product, a mouse embryonic stem cell growth medium, has been exclusively licensed for manufacture and marketing to Chemicon, a division of Serologicals Inc. SC Licensing licenses its proprietary technologies such as Internal Ribosome Entry Site (IRES) and Stem Cell Selection for application in laboratory-based research and discovery. SC Services will provide cell production for research and high-throughput drug screening.

SC Therapies first program is being undertaken by SCS's Japanese affiliate, which recently announced the exclusive licensing of human multipotent adipocyte-derived (hMads) for use in an experimental cell based therapy programme against Duchenne's Muscular Dystrophy that will form the basis for a degenerative diseases focused pre-clinical programme.

SCS plc is a global Group with operations in the UK, Australia and Japan. Each company is affiliated with academic stem cell centers of excellence in order to access and commercialize new IP developing in the field. These include the Institute of Stem Cell Research, Edinburgh, UK; RIKEN Centre for Development Biology, Japan and the Australian Stem Cell Centre, Melbourne, Australia.

SCS, which listed on the London Alternative Investment Market in July 2005, was founded in 1994 to commercialize findings from the Institute of Stem Cell Research at the University of Edinburgh, UK, and Monash University, Melbourne, Australia. The Company is a participant in two research projects under the European Union's Framework Six Programme for Research and Technology Development and is a contributor to the UK Stem Cells Initiative.

For further information please visit the corporate website at: http://www.stemcellsciences.com/.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as "should result," "are expected to," "we anticipate," "we estimate," "we project" or similar expressions are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements.

You should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made, and the Company undertakes no obligation to update these statements based on events that may occur after the date of this press release.

Serologicals is a registered trademark of Serologicals Royalty Company.